SNDX - Syndax: Gearing Up For Launches

2024-06-21 05:50:25 ET

Summary

• Syndax Pharmaceuticals has upcoming Q3 PDUFAs for revumenib and axatilimab, both awarded priority review.
• Syndax pegs both upcoming PDUFAs as potential blockbusters once approved, with revumenib offering a larger revenue opportunity.
• Syndax's value as an investment depends on FDA approvals and successful commercialization of its molecules, making it a speculative high-risk investment.

This is my second Syndax Pharmaceuticals ( SNDX ) article, following 03/2024's "Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope" (" Hope "). At the time, Syndax was trading at $23.18, I rated it a speculative "Buy" with its rich market cap hovering near $2 billion; currently as I write it trades at $19.26 with a market cap of $1.62 billion....

For further details see: